TG Therapeutics
TGTX
NASDAQ
IPO1995
about TGTX
TG Therapeutics is a biopharmaceutical company focused on developing innovative treatments for cancers such as lymphoma and leukemia, immune-mediated diseases like psoriasis, and other conditions, with key products including umilast, an oral disease-modifying therapy in late-stage development.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $28.75 | $29.46 | $28.25 | $4.6B | 1.33M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$2.69 | 10.95 | 28.88 | 18.16% | 241.73% | 0% |